The way the pharma industry has traditionally handled clinical trials does not make participation easy.

We speak with the authors of two studies into extreme increases in US drug pricing, and attempts by lawmakers to bring the price-jackers into line.

With the threat of COVID-19, vaccine developers needed to enter clinical development and scale-up at unprecedented speed.

What lessons were learned from Operation Warp Speed?

We get the lowdown on the Reputation Index, which was recently published by the Association of the British Pharmaceutical Industry.

The pharma industry is one of the biggest targets for cybercrime. How can companies avoid succumbing to attack?

Work at the Max Planck Institute of Molecular Physiology has revealed a welcome surprise: a potential new class of COVID-19 drugs.

Sitting Down With… Evelina Vågesjö, Chief Executive Officer at Ilya Pharma, Sweden.

On the 70th anniversary of death Henrietta Lacks, we examine her contributions to science and what they mean for modern research.

Mike Rea of IDEA Pharma shares his thoughts on what players pharma in positioning are getting right – and wrong.